Vernalis spikes troubled V3381 program

The U.K'.s Vernalis says that interim data from a pilot study of V3381 for chronic cough along with the data from a Phase IIb study in neuropathic pain convinced the developer to spike any further plans to develop the therapy. Vernalis' shares were hammered back in March after the company announced that V3381 had flunked the IIb study. Once one of the U.K.'s biggest biotech companies, repeated clinical failures have steadily chipped away at its value. Vernalis release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.